Parameter
| Biomarker | TERT Promoter Mut | Full name | TERT Promoter Mutation | Molecular Type | Gene Mutation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, Risk Stratification |
| Disease | Meningioma | Disease Subtypes | / | ||
| Organ | Brain, Meninges | Test Sample / Technology Platform | Tumor Tissue (Pyrosequencing, NGS) | ||
| Pathobiological Mechanisms | Enhances telomerase activity, maintains the unlimited proliferation capacity of tumor cells, and is associated with malignant progression. | ||||
| Clinical Availability Status | Under Clinical Validation | ||||
| Notes and Dynamics | An independent poor prognostic indicator regardless of WHO grade; the median progression time of mutant patients is shortened to 10 months. | ||||